The Role of Genomics in the Management of Advanced Bladder Cancer

Current Treatment Options in Oncology

Volumn 16, Issue 1, 2015, Pages

  Guancial, Elizabeth A ^a   Rosenberg, Jonathan E ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bladder cancer; Chemotherapy; Genome sequencing; Genomics; Molecular targets; Mutations; Platinum; Targeted therapy; Urothelial carcinoma

Indexed keywords

3 (2,6 DICHLORO 3,5 DIMETHOXYPHENYL) 1 [6 [[4 (4 ETHYL 1 PIPERAZINYL)PHENYL]AMINO] 4 PYRIMIDINYL] 1 METHYLUREA; ALPELISIB; APATORSEN; BEVACIZUMAB; BUPARLISIB; CABOZANTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DENDRITIC CELL VACCINE; DOCETAXEL; DOVITINIB; DOXORUBICIN; EVEROLIMUS; GEFITINIB; GEMCITABINE; LAPATINIB; METHOTREXATE; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; UNINDEXED DRUG; VANDETANIB; VINBLASTINE; VINFLUNINE; ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

ADVANCED CANCER; BLADDER CANCER; CANCER CLASSIFICATION; CANCER GENETICS; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENOMICS; GERMLINE MUTATION; HISTONE MODIFICATION; HUMAN; LIFE EXPECTANCY; NEXT GENERATION SEQUENCING; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TRANSITIONAL CELL CARCINOMA; GENETICS; MUTATION; PHARMACOGENETICS; PROCEDURES; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS; GENOMICS; HUMANS; MUTATION; NEOPLASM PROTEINS; PHARMACOGENETICS; URINARY BLADDER NEOPLASMS;

EID: 84924359606     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-014-0319-z     Document Type: Review

References (95)

1. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066–73.
2. Parekh DJ, Bochner BH, Dalbagni G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J Clin Oncol. 2006;24:5519–27.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
4. Abdollah F, Gandaglia G, Thuret R, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013;37:219–25.
5. Ortmann CA, Mazhar D. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder. Future Oncol. 2013;9:1637–51.
6. Galsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012;23:406–10.
7. Morales-Barrera R, Suarez C, Valverde C, et al. Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy? Clin Transl Oncol. 2014;16:102–6.
8. Morrison CD, Liu P, Woloszynska-Read A, et al. Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc Natl Acad Sci U S A. 2014;111:E672–81. This report describes the complete genome analysis of five muscle-invasive bladder cancers and reports findings of chromothripsis secondary to nonhomologous end-joining.
9. Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152–65. This article characterizes intrinsic subtypes of bladder cancer and discusses potential genomic explanations for differential chemosensitivity between groups.
10. Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014;111:3110–5. This report highlights similarities between the intrinsic subtypes of bladder cancer independently identified by this group and well-established subtypes of breast cancer.
11. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–22. This study is an integrated genomic analysis that comprehensively catalogs alterations in bladder cancer, including mutations not previously identified in cancer.
12. Iyer G, Al-Ahmadie H, Schultz N, et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol. 2013;31:3133–40. This integrative analysis revealed actionable genomic alterations in the majority of high-grade bladder tumors studied.
13. Ross JS, Wang K, Al-Rohil RN, et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol 2013;27:271–80. This comprehensive next-generation sequencing study of 35 metastatic bladder cancers reports the prevalence of genomic alterations.
14. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5:713–25.
15. Tran B, Dancey JE, Kamel-Reid S, et al. Cancer genomics: technology, discovery, and translation. J Clin Oncol. 2012;30:647–60. This timely review provides an introduction to the rapidly developing field of genomics as applied to oncology.
16. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338:221. This report was the first to identify an underlying molecular mechanism for response to a targeted agent in bladder cancer based on genomic sequencing.
17. Wagle N, Grabiner BC, Van Allen EM, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014;4:546–53. Similar to the report by Iyer at al., this paper describes molecular mechanisms for sensitivity to everolimus and pazopanib in one patient with bladder cancer.
18. Milowsky MI, Iyer G, Regazzi AM, et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int. 2013;112:462–70.
19. Choi W, Czerniak B, Ochoa A, et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014;11:400–10. This is an excellent review that summarizes the current understanding of molecular subtypes of bladder cancer and draws parallels with breast cancer subtypes.
20. US Na. Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients with Bladder Cancer. June 2014. Accessed 23 Jul 2013.
21. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A. 2007;104:13086–91.
22. Gui Y, Guo G, Huang Y, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 2011;43:875–8.
23. Guo G, Sun X, Chen C, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet. 2013;45:1459–63.
24. Solomon DA, Kim JS, Bondaruk J, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet. 2013;45:1428–30.
25. Taylor CF, Platt FM, Hurst CD, Thygesen HH, Knowles MA. Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. Hum Mol Genet. 2014;23:1964–74.
26. Balbas-Martinez C, Sagrera A, Carrillo-de-Santa-Pau E, et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet. 2013;45:1464–9.
27. Sapre N, Herle P, Anderson PD, Corcoran NM, Hovens CM. Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder. Pathology. 2014;46:274–82. This is a thorough review of the development of prognostic genetic and epigenetic molecular biomarkers for bladder cancer, including non-muscle invasive disease.
28. Bambury RM, Rosenberg JE. Actionable mutations in muscle-invasive bladder cancer. Curr Opin Urol. 2013;23:472–8. This review provides a concise discussion of known actionable mutations and therapeutic implications for muscle-invasive bladder cancer.
29. Riester M, Taylor J, Feifer A, et al. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res. 2012;18:1323–33.
30. Kim WJ, Kim SK, Jeong P, et al. A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol Med. 2011;17:478–85.
31. Kim WT, Kim J, Yan C, et al. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy. Ann Oncol. 2014;25:974–9.
32. Gallagher DJ, Vijai J, Hamilton RJ, et al. Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host. Ann Oncol. 2013;24:2414–21.
33. Nordentoft I, Birkenkamp-Demtroder K, Agerbaek M, et al. MiRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics. 2012;5:40. 8794–5–40.
34. Yu HJ, Chang YH, Pan CC. Prognostic significance of heat shock proteins in urothelial carcinoma of the urinary bladder. Histopathology 2012;62:788–98.
35. Acquaviva J, He S, Zhang C, et al. FGFR3 Translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism. Mol Cancer Res. 2014;12:1042–54.
36. Acquaviva J, He S, Sang J, et al. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis. Mol Cancer Res. 2014;12:703–13.
37. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;202. 5; discussion 205–6. This meta-analysis reports the overall survival benefit of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
38. Patafio FM, Mackillop WJ, Feldman-Stewart D, Siemens DR, Booth CM. Why is perioperative chemotherapy for bladder cancer underutilized? Urol Oncol. 2014;32:391–5.
39. Booth CM, Siemens DR, Li G, et al. Perioperative chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study. Cancer. 2014;120:1630–8.
40. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–8.
41. Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014;32:1895–901.
42. Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014;32:1889–94.
43. Sternberg CN, Skoneczna IA, Kerst JM, et al. Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder. J Clin Oncol. 2014;32(Suppl):abstr 4500. This abstract provides the most recent data on the potential benefit of adjuvant chemotherapy in muscle-invasive bladder cancer following cystectomy.
44. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107:506–13.
45. Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29:2432–8. This commentary provides recommendations for the management of patients with metastatic bladder cancer who are ineligible for cisplatin-chemotherapy based on expert consensus.
46. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454–61.
47. Clark PE, Agarwal N, Biagioli MC, et al. Bladder cancer (Version 2.2014). J Natl Compr Cancer Netw. 2014;2014:446–75.
48. Guancial EA, Werner L, Bellmunt J, et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014;3(4):835–44.
49. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 2013;22:795–803.
50. Milowsky MI, Dittrich C, Martinez ID, et al. Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3. J Clin Oncol. 2013;(Suppl 6):abst 255.
51. US National Library of Medicine. Phase 1b Trial of BGJ398/BYL719 in Solid Tumors February 2014. Accessed 5 Jul 2014.
52. US National Library of Medicine. BGJ398 for Patients with Tumors with FGFR Genetic Alterations July 2014. Accessed 13 Jul 2014.
53. US National Library of Medicine. A Dose Escalation Study in Adult Patients with Advanced Solid Malignancies July 2014. Accessed 15 Jul 2014.
54. Chaux A, Cohen JS, Schultz L, et al. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. Hum Pathol. 2012;43:1590–5.
55. Ghosh M, Brancato SJ, Agarwal PK, Apolo AB. Targeted therapies in urothelial carcinoma. Curr Opin Oncol. 2014;26:305–20. This is a comprehensive update of completed and ongoing clinical trials of targeted therapy in non-muscle invasive and muscle invasive bladder cancer.
56. US National Library of Medicine. PURO Panitumumab in Combination with Gemcitabine/Cisplatin in Advanced Urothelial Cancer March 2014. Accessed 5 Jul 2014.
57. US National Library of Medicine. Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer May 2013. Accessed 1 Oct 2014.
58. Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol. 2011;60:350–7.
59. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007;25:2218–24.
60. US National Library of Medicine. Lapatininb, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients with Locally Advanced or Metastatic Urothelial Cancer June 2014. Accessed 5 Jul 2014.
61. US National Library of Medicine. Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma of the Bladder February 2014. Accsssed 15 Jul 2014.
62. US National Library of Medicine. A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium (LaMB) July 2014. Accessed 15 Jul 2014.
63. US National Library of Medicine. Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing April 2013. Accessed 15 Jul 2014.
64. Kopparapu PK, Boorjian SA, Robinson BD, et al. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res. 2013;33:2381–90.
65. Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol. 2009;27:391–9.
66. Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011;29:1525–30.
67. Balar AV, Apolo AB, Ostrovnaya I, et al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol. 2013;31:724–30.
68. US National Library of Medicine. Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients with Advanced Urinary Tract Cancer June 2014. Accessed 15 Jul 2014.
69. Bellmunt J, Maroto P, Mellado B, et al. Phase II study of sunitinib as first line treatment in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy. ASCO Meet Abstr. 2008;26:291.
70. Sridhar SS, Winquist E, Eisen A, et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs. 2010;29:1045–9.
71. Dreicer R, Li H, Stein M, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer. 2009;115:4090–5.
72. Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol. 2010;28:1373–9.
73. Galsky MD, Hahn NM, Powles T, et al. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2013;11:175–81.
74. Krege S, Rexer H, vom Dorp F, et al. Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05). BJU Int. 2014;113:429–36.
75. US National Library of Medicine. Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients with Advanced/Metastatic Bladder Carcinoma June 2014. Accessed 15 Jul 2014.
76. US National Library of Medicine. Phase I Study with Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (VINSOR) April 2013. Accessed 5 Jul 2014.
77. Necchi A, Mariani L, Zaffaroni N, et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol. 2012;13:810–6.
78. Pili R, Qin R, Flynn PJ, et al. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer. 2013;11:477–83.
79. Gerullis H, Eimer C, Ecke TH, Georgas E, Arndt C, Otto T. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy. Anticancer Drugs. 2013;24:422–5.
80. US National Library of Medicine. Gemcitabine and Pazopanib in Chemotherapy Naive Patients with Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy February 2014. Accessed 5 Jul 2014.
81. US National Library of Medicine. Phase II Pazopanib in Combination with Weekly Paclitaxel in Refractory Urothelial Cancer July 2014. Accessed 15 Jul 2014.
82. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:553–72.
83. US National Library of Medicine. Cabozantinib for Advanced Urothelial Cancer June 2014; July 5, 2014.
84. Bellmunt J, Teh BT, Tortora G, Rosenberg JE. Molecular targets on the horizon for kidney and urothelial cancer. Nat Rev Clin Oncol. 2013;10:557–70. This recent review focuses on the use of whole-genome sequencing in the identification of therapeutic targets in non-hormonally driven urothelial cancers, including bladder cancer.
85. Seront E, Rottey S, Sautois B, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol. 2012;23:2663–70.
86. US National Library of Medicine. Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients with Advanced Solid Tumor Malignancies April 2014. Accessed 5 Jul 2014.
87. US National Library of Medicine. First-line Everolimus ± Paclitaxel for Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma April 2014. Accessed 5 Jul 2014.
88. US National Library of Medicine. Gemcitabine Hydrocholoride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients with Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium August 2013. Accessed 15 Jul 2014.
89. US National Library of Medicine. Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients with Advanced Bladder Cancer (VESTOR) April 2013. Accessed 5 Jul 2014.
90. Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30:282–90.
91. US National Library of Medicine. Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium July 2014. Accessed 15 Jul 2014.
92. Kamada M, So A, Muramaki M, Rocchi P, Beraldi E, Gleave M. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther. 2007;6:299–308.
93. Garg M, Kanojia D, Seth A, et al. Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. Eur J Cancer. 2010;46:207–15.
94. US National Library of Medicine. A Phase 2 Study Comparing Chemotherapy in Combination with OGX-427 or Placebo in Patients with Bladder Cancer July 2013. Accessed 5 Jul 2014.
95. US National Library of Medicine. Phase 2 Study of Docetaxel ± OGX-427 in Patient with Relapsed or Refractory Metastatic Bladder Cancer June 2014. Accessed 15 Jul 2014.